Kyntra Bio (KYNB) Gross Margin (2018 - 2026)
Kyntra Bio (KYNB) posted Gross Margin of 9.84% for Q1 2026, down 112.58% sequentially from 78.23% in Q4 2025, and down 10064.0% YoY from N/an in Q1 2025.
Kyntra Bio (KYNB) Gross Margin (2018 - 2026) Analysis & Trends
Kyntra Bio has reported Gross Margin for 9 years, with the latest figure at 9.84% in Q1 2026.
- Quarterly Gross Margin fell 10064.0% year-over-year to 9.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39.15% (down 14494.0% YoY) and the FY2025 annual result came in at 91.37%, up 4390.0% from the prior year.
- Gross Margin retreated to 9.84% in Q1 2026 per KYNB's latest filing, from 78.23% in the prior quarter.
- Over five years, Gross Margin peaked at 286.48% in Q4 2024 and troughed at 859.09% in Q1 2024.
- A 5-year average of 15.2% and a median of 72.62% in 2022 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2024 and 2025: Gross Margin tumbled 75374 bps in 2024, then soared 94989 bps in 2025.
- Over 5 years, Gross Margin stood at 41.37% in 2022, then soared by 111 bps to 87.16% in 2023, then soared by 229 bps to 286.48% in 2024, then tumbled by 73 bps to 78.23% in 2025, then slumped by 113 bps to 9.84% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 9.84%, 78.23%, and 94.61% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | - |
| 10 | Kyntra Bio | 30.40 Mn | 30.40 Mn | 1.47 Mn | 99.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.86% |
| Mar 31, 2026 | -9.84% |
| Dec 31, 2025 | 78.23% |
| Sep 30, 2025 | 94.61% |
| Jun 30, 2025 | 93.69% |
| Mar 31, 2025 | 90.80% |
| Dec 31, 2024 | 286.48% |
| Sep 30, 2024 | 39.02% |
| Jun 30, 2024 | 65.00% |
| Mar 31, 2024 | -859.09% |
| Dec 31, 2023 | 87.16% |
| Sep 30, 2023 | 89.43% |
| Jun 30, 2023 | 60.36% |
| Mar 31, 2023 | -105.35% |
| Dec 31, 2022 | 41.37% |
| Sep 30, 2022 | 72.62% |
| Jun 30, 2022 | 77.16% |
| Mar 31, 2022 | 56.76% |
| Dec 31, 2021 | 81.11% |
| Sep 30, 2021 | 97.91% |